Trials / Sponsors / Marker Therapeutics, Inc.
Marker Therapeutics, Inc.
Industry · 6 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Safety of MT-401-OTS in Patients With Relapsed AML or MDS Acute Myeloid Leukemia, in Relapse, MDS | Phase 1 | 2025-06-16 |
| Not Yet Recruiting | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Pancreas Cancer | Phase 1 | 2024-09-01 |
| Recruiting | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed | Phase 1 | 2023-01-02 |
| Terminated | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Acute Myeloid Leukemia, Stem Cell Transplantation | Phase 2 | 2020-10-14 |
| Terminated | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovar Platinum Sensitive Ovarian Cancer, Ovarian Cancer | Phase 2 | 2017-07-20 |
| Completed | Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer Breast Cancer | Phase 2 | 2016-04-01 |